The previously published Phase II study NCT00658437 in patients with metastatic skin cancer (melanoma) (Trefzer et al. 2014) was subjected to an extended evaluation, because a relationship between the occurrence of local skin reactions after subcutaneous injection of ME-503 and the clinical effect of the treatment was considered possible. The extended evaluation thus referred to the phase II data of the patient cohorts with/without skin reactions within the first treatment cycle after SC injection. There was a highly significant difference in median overall survival in patients with injection site reactions compared to patients without skin reactions. Preliminary conclusions from our small cohorts indicate a robust clinical impact of ME-503 in patients with previously treated metastatic melanoma when these patients experience […]